Enterprise Value
151.8B
Cash
8.73B
Avg Qtr Burn
N/A
Short % of Float
1.77%
Insider Ownership
0.07%
Institutional Own.
78.21%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Sotyktu (deucravacitinib) Details Psoriasis, Skin disease/disorder | Approved Quarterly sales | |
Eliquis Details Stroke, Atrial fibrillation, Blood clots | Approved Quarterly sales | |
Opdivo® (nivolumab) + chemotherapy Details Cancer, Non-small cell lung carcinoma | Approved Quarterly sales | |
Reblozyl®(luspatercept-aamt) Details Cancer, Blood cancer, Mutant Myelodysplastic Syndromes, Anemia | Approved Quarterly sales | |
Camzyos®(mavacamten) Details Hypertrophic cardiomyopathies | Approved Quarterly sales | |
Abecma (idecabtagene vicleucel) Details Cancer, Melanoma | PDUFA Approval decision | |
Repotrectinib (ROS1/TRK inhibitor) Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | PDUFA Approval decision | |
Opdivo® (nivolumab) Details Cancer, Melanoma | PDUFA Approval decision | |
Milvexian Details Stroke, Atrial fibrillation, Acute coronary syndrome | Phase 3 Data readout | |
Opdivo® (nivolumab) + relatlimab w/ ENHANZE® Details Cancer, Melanoma | Phase 3 Update | |
Breyanzi® (lisocabtagene maraleucel) Details B-cell lymphoma | Phase 3 Update | |
Opdivo® (nivolumab) + Yervoy (ipilimumab) Details Non-small cell lung carcinoma, Cancer | Phase 3 Update | |
BMS-986278 [(LPA1) antagonist] Details Idiopathic pulmonary fibrosis, Lung disease | Phase 3 Initiation | |
Breyanzi® (lisocabtagene maraleucel) Details Blood cancer, Small lymphocytic lymphoma , Chronic lymphocytic leukemia | Phase 2 Data readout | |
A/I CELMoD (CC-99282) Details Non-Hodgkin lymphoma, Cancer, Relapsed/ refractory lymphoma | Phase 2 Interim update | |
Breyanzi® (lisocabtagene maraleucel) Details B-cell lymphoma, Non-Hodgkin lymphoma, Follicular lymphoma | Phase 2 Update | |
Elzovantinib (TPX-0022) (MET inhibitor) Details Solid tumor/s, Cancer | Phase 2 Initiation | |
Repotrectinib (ROS1/TRK inhibitor) Details Solid tumor/s, Cancer | Phase 1/2 Update | |
Breyanzi® (lisocabtagene maraleucel) Details Non-Hodgkin lymphoma, B-cell lymphoma, Mantle cell lymphoma | Phase 1 Update |